Taro Recalls Clobetasol Propionate Cream Due to Content Uniformity Failure
Taro Pharmaceuticals is recalling 27,792 tubes of Clobetasol Propionate Cream 0.05% because the product failed content uniformity specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which indicates the product is not likely to cause adverse health consequences. The failure of content uniformity specifications is a quality control issue that may result in inconsistent dosing, but no specific injuries or illnesses are reported in the source text.
Plain-English summary
Taro Pharmaceuticals U.S.A., Inc. is recalling 27,792 tubes of Clobetasol Propionate Cream USP, 0.05%, 60 g. The recall was initiated because the product failed content uniformity specifications. The affected product is identified by Lot 311235 with an expiration date of September 2018.
The recalled product was distributed nationwide. It is a prescription-only topical medication manufactured by Taro Pharmaceutical Industries Ltd. in Israel and distributed by Taro Pharmaceuticals U.S.A., Inc. in Hawthorne, NY.
Consumers should stop using the recalled product and return it to their pharmacy or contact their healthcare provider for further instructions.
The recalled product
- Product
- CLOBETASOL PROPIONATE (CLOBETASOL PROPIONATE)
- Brand
- CLOBETASOL PROPIONATE
- Manufacturer
- Taro Pharmaceuticals U.S.A., Inc.
- Category
- Drug — Topical Steroid
- Hazard
- Affected units
- 27,792
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot 311235
- exp Sept 2018
UPCs (2)
- 0351672129422
- 351672125837
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · CLOBETASOL PROPIONATE
- ModerateLupin Recalls Clobetasol Propionate Cream for Content Uniformity Failures
FDA (Drugs) · 2026-09-02
- ModerateClobetasol Propionate Cream recalled due to subpotent drug
FDA (Drugs) · 2023-02-01
- SevereClobetasol Propionate Ointment Recalled for Microbial Contamination
FDA (Drugs) · 2022-01-19
- LowGlenmark Recalls Clobetasol Propionate Foam Due to Defective Delivery System
FDA (Drugs) · 2019-12-18
- LowGlenmark Recalls Clobetasol Propionate Foam Due to Defective Delivery System
FDA (Drugs) · 2019-12-18
Same manufacturer · Taro Pharmaceuticals U.S.A., Inc.
See all →- ModerateHydrocortisone & Acetic Acid Otic Solution Recalled for Potency and Impurity Failures
FDA (Drugs) · 2024-08-21
- ModerateClotrimazole and Betamethasone Topical Cream Recalled for Failed Potency Specifications
FDA (Drugs) · 2022-04-06
- HighTaro Recalls Nortriptyline Hydrochloride Capsules Due to Manufacturing Deviations
FDA (Drugs) · 2021-02-10
- ModerateTaro Recalls Rite Aid Clotrimazole Cream Due to Impurity
FDA (Drugs) · 2020-12-23
- ModerateTaro Recalls Clotrimazole Cream Due to Unknown Degradation Impurity
FDA (Drugs) · 2020-12-23
Same hazard · content uniformity
See all →- HighOral contraceptive tablets recalled after failing content uniformity specifications
FDA (Drugs) · 2025-10-15
- HighCefixime Oral Suspension Recalled for Failed Content Uniformity Specifications
FDA (Drugs) · 2024-06-26
- SevereFDA Recalls Phenytoin Oral Suspension Due to Content Uniformity Failure
FDA (Drugs) · 2023-12-27
- ModerateDofetilide Capsules Recalled Due to Out-of-Specification Content Uniformity
FDA (Drugs) · 2023-08-16
- ModerateDofetilide Capsules Recalled for Failed Content Uniformity Specifications
FDA (Drugs) · 2023-03-29